Found: 69
Select item for more details and to access through your institution.
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 5, p. N.PAG, doi. 10.1016/j.clgc.2024.102172
- By:
- Publication type:
- Article
Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature.
- Published in:
- Oncologist, 2009, v. 14, n. 8, p. 816, doi. 10.1634/theoncologist.2009-0043
- By:
- Publication type:
- Article
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
- Published in:
- Cancers, 2022, v. 14, n. 15, p. 3830, doi. 10.3390/cancers14153830
- By:
- Publication type:
- Article
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 5872, doi. 10.3390/cancers13235872
- By:
- Publication type:
- Article
The Value of Phenotypic Precision Medicine in Prostate Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 2, p. 93, doi. 10.1093/oncolo/oyac198
- By:
- Publication type:
- Article
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 33, doi. 10.1093/oncolo/oyac164
- By:
- Publication type:
- Article
Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.
- Published in:
- World Journal of Men's Health, 2023, v. 41, n. 3, p. 631, doi. 10.5534/wjmh.220068
- By:
- Publication type:
- Article
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
- Published in:
- Nucleic Acids Research, 2019, v. 47, n. 19, p. 10104, doi. 10.1093/nar/gkz790
- By:
- Publication type:
- Article
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
- Published in:
- Clinical Medicine Insights: Oncology, 2011, n. 5, p. 325, doi. 10.4137/CMO.S5977
- By:
- Publication type:
- Article
Circulating Tumor Cell Phenotyping via High‐Throughput Acoustic Separation.
- Published in:
- Small, 2020, v. 16, n. 34, p. 1, doi. 10.1002/smll.202004438
- By:
- Publication type:
- Article
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
- Published in:
- 2020
- By:
- Publication type:
- letter
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Dasatinib combined with docetaxel for castration-resistant prostate cancer.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 1, p. 63, doi. 10.1002/cncr.26204
- By:
- Publication type:
- Article
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 17, p. 3963, doi. 10.1002/cncr.25982
- By:
- Publication type:
- Article
Injuries involving the central tarsal bone in nonracing dogs: Short‐term outcomes and prognostic factors.
- Published in:
- Veterinary Surgery, 2019, v. 48, n. 4, p. 524, doi. 10.1111/vsu.13187
- By:
- Publication type:
- Article
Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00363-2
- By:
- Publication type:
- Article
Anti-angiogenic therapy in renal cell cancer.
- Published in:
- BJU International, 2007, v. 99, p. 1296, doi. 10.1111/j.1464-410X.2007.06834.x
- By:
- Publication type:
- Article
In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 10, p. 881
- By:
- Publication type:
- Article
What to Order From the Prostate Cancer Treatment Menu?
- Published in:
- Oncology (08909091), 2012, v. 26, n. 1, p. 84
- By:
- Publication type:
- Article
The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
- Published in:
- Prostate, 2022, v. 82, n. 13, p. 1237, doi. 10.1002/pros.24396
- By:
- Publication type:
- Article
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2022, v. 82, n. 7, p. 858, doi. 10.1002/pros.24329
- By:
- Publication type:
- Article
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer.
- Published in:
- Prostate, 2019, v. 79, n. 15, p. 1752, doi. 10.1002/pros.23899
- By:
- Publication type:
- Article
Patterns of response and progression in bone and soft tissue during and after treatment with radium‐223 for metastatic castrate‐resistant prostate cancer.
- Published in:
- Prostate, 2019, v. 79, n. 10, p. 1106, doi. 10.1002/pros.23822
- By:
- Publication type:
- Article
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
- Published in:
- Prostate, 2017, v. 77, n. 4, p. 385, doi. 10.1002/pros.23277
- By:
- Publication type:
- Article
Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 22, p. 1729, doi. 10.1093/jnci/djt280
- By:
- Publication type:
- Article
Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens.
- Published in:
- 2008
- By:
- Publication type:
- Letter
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
- Published in:
- Prostate, 2024, v. 84, n. 3, p. 292, doi. 10.1002/pros.24650
- By:
- Publication type:
- Article
The promise of immunotherapy in genitourinary malignancies.
- Published in:
- Precision Clinical Medicine, 2018, v. 1, n. 3, p. 97, doi. 10.1093/pcmedi/pby018
- By:
- Publication type:
- Article
Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution.
- Published in:
- Clinical Journal of Oncology Nursing, 2015, v. 19, n. 3, p. 297, doi. 10.1188/15.CJON.297-303
- By:
- Publication type:
- Article
Tumor Cell Phenotyping: Circulating Tumor Cell Phenotyping via High‐Throughput Acoustic Separation (Small 32/2018).
- Published in:
- Small, 2018, v. 14, n. 32, p. 1, doi. 10.1002/smll.201870145
- By:
- Publication type:
- Article
Circulating Tumor Cell Phenotyping via High‐Throughput Acoustic Separation.
- Published in:
- Small, 2018, v. 14, n. 32, p. 1, doi. 10.1002/smll.201801131
- By:
- Publication type:
- Article
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00978-z
- By:
- Publication type:
- Article
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
- Published in:
- PLoS ONE, 2019, v. 14, n. 5, p. 1, doi. 10.1371/journal.pone.0216934
- By:
- Publication type:
- Article
Highlights in Prostate Cancer From the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 3, p. 112
- By:
- Publication type:
- Article
Update on Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 5, p. 277
- By:
- Publication type:
- Article
Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, p. 16
- By:
- Publication type:
- Article
Prostate-Specific Membrane Antigen-Targeted Theranostics: Past, Present, and Future Approaches.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 4, p. 227
- By:
- Publication type:
- Article
Highlights in Advanced Prostate Cancer From the 2021 American Society of Clinical Oncology Annual Meeting: A Review of Selected Presentations From the 2021 ASCO Annual Meeting.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, p. 1
- By:
- Publication type:
- Article
Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.
- Published in:
- Journal of Pathology, 2023, v. 260, n. 1, p. 43, doi. 10.1002/path.6063
- By:
- Publication type:
- Article
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
- Published in:
- Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00334-4
- By:
- Publication type:
- Article
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.
- Published in:
- Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00267-y
- By:
- Publication type:
- Article
Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy.
- Published in:
- Asian Journal of Andrology, 2011, v. 13, n. 2, p. 179, doi. 10.1038/aja.2010.169
- By:
- Publication type:
- Article
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 145, doi. 10.1007/s10637-023-01410-2
- By:
- Publication type:
- Article
Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects.
- Published in:
- Therapeutic Advances in Urology, 2016, v. 8, n. 1, p. 9, doi. 10.1177/1756287215603558
- By:
- Publication type:
- Article
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 11, p. e2134330, doi. 10.1001/jamanetworkopen.2021.34330
- By:
- Publication type:
- Article